Trial Profile
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 01 Mar 2024 Planned End Date changed from 31 May 2020 to 28 Feb 2025.
- 16 Jun 2020 Planned primary completion date changed from 31 May 2020 to 31 May 2021.
- 03 Jun 2019 Primary endpoint (Complete response rate, defined to be a complete hematologic response (CR) or complete response incomplete (CRi) noted as the objective status at any time during treatment) has not been met, according to Results (n=16) published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).